Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease.

Journal of internal medicine - 1 Jan 2025

Ahmed Osman, Shavva Vladimir S, Tarnawski Laura, Dai Wanmin, Borg Filip, Olofsson Viggo V, Liu Ting, Saliba-Gustafsson Peter, Simini Christian, Pedrelli Matteo, Bergman Otto, Norata Giuseppe Danilo, Parini Paolo, Franco-Cereceda Anders, Eriksson Per, Malin Stephen G, Björck Hanna M, Olofsson Peder S

Abstract excerpt

BACKGROUND AND OBJECTIVES: Statins are used for metabolic dysfunction-associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin-like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyltransferases
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipase

Share to Lipogenesis

Share to Metabolic Syndrome

Share to Non-alcoholic Fatty Liver Disease

Share to Phospholipases A2, Calcium-Independent

Source

Open in PubMed Open full text

Identifiers

PMID: 39560367
DOI: 10.1111/joim.20032
PMCID: PMC11636427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease.PMID 39560367Read ↗

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and TherapeuticsSemantic proximity Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular CrosstalkSemantic proximity Read ↗

Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH SettingsSemantic proximity Read ↗

Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.Semantic proximity Read ↗

Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatmentSemantic proximity Read ↗

PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.Semantic proximity Read ↗

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.Semantic proximity Read ↗

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.Semantic proximity Read ↗

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.Semantic proximity Read ↗

PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.